ArticleClinical and experimental medicine2025
CSRP1 is a potential therapeutic targets for DLBCL: A computational analysis and in vitro experiments.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
At present, the role of Cysteine and glycine rich protein 1 (CSRP1) in the occurrence and development of diffuse large B lymphoma (DLBCL) has not been reported. We conducted a comprehensive analysis of the potential value of CSRP1 in DLBCL using multiple independent datasets and analytical methods, including differential expression analysis, pathway analysis and immune analysis. Then, cell experiments were used to confirm the regulatory role of CSRP1 in DLBCL. The analysis results show that in DLBCL patients, the expression of CSRP1 is significantly upregulated. In addition, CSRP1 is associated with the cell cycle related pathways and immune microenvironment in DLBCL. Cell experiments confirmed that CSRP1 can significantly regulate the apoptosis and cycle progression of DLBCL cells. In conclusion, CSRP1 may be a potential therapeutic target for DLBCL patients, our research provides a theoretical basis for improving the clinical treatment of DLBCL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.